PAROGRELIL HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H18BrClN4O2.ClH
Molecular Weight	486.19
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.ClC1=CC=C(CCCOC2=NNC(=O)C(Br)=C2NCC3=CN=CC=C3)C=C1

InChI

InChIKey=QWGUGDYWUADMGB-UHFFFAOYSA-N

InChI=1S/C19H18BrClN4O2.ClH/c20-16-17(23-12-14-3-1-9-22-11-14)19(25-24-18(16)26)27-10-2-4-13-5-7-15(21)8-6-13;/h1,3,5-9,11H,2,4,10,12H2,(H2,23,24,26);1H

HIDE SMILES / InChI

Molecular Formula	C19H18BrClN4O2
Molecular Weight	449.729
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.businesswire.com/news/home/20060313005348/en/Nissan-Chemical-Reports-Positive-Phase-IIb-Study
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19616537

NT-702 (parogrelil hydrochloride) is a novel phosphodiesterase 3 (PDE) inhibitor, and being developed for the treatment of intermittent claudication (IC) in patients with peripheral arterial disease. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and asthma. In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed. Also was shown, that NT-702 has an anti-inflammatory effect as well as a bronchodilating effect and might be useful as a novel potent therapeutic agent with both a bronchodilating and an anti-inflammatory effect.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 3 61 Target ID: CHEMBL2094125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19616537	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Intermittent claudication 12 Sources: https://clinicaltrials.gov/ct2/show/NCT00102050	Palliative		Phase II 1147	Unknown Approved Use Unknown
Peripheral arterial disease 22 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17174195	Palliative		Phase II 1147	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific	3784AL	https://aksci.com/item_detail.php?cat=3784AL
Axon MedChem	1482	https://www.axonmedchem.com/product/1482
BLD Pharm	BD448287	http://www.bldpharm.com/search/Search.html?keyword=BD448287
BOC Sciences	139145-27-0	http://www.bocsci.com/description.asp?cas=139145-27-0
Combi-Blocks	QJ-7959	http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-7959
eMolecules	36367106	https://orderbb.emolecules.com/search/#?query=36367106
MolPort	MolPort-021-804-987	https://www.molport.com/shop/molecule-link/MolPort-021-804-987
MuseChem	M110551	https://www.musechem.com/product/M110551.html
ShangHai Biochempartner	BCP02174	http://www.biochempartner.com/search_BCP02174

PubMed

Title	Date	PubMed
		252160181
Optimal assessment of baseline treadmill walking performance in claudication clinical trials.	2007 May	17615797
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.	2007 Sep 1	17850826
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects.	2009 Sep 15	19616537

Patents

Sample Use Guides

In Vivo Use Guide

4 mg and/or 8 mg PAROGRELIL taken twice a day for 24 weeks

Route of Administration: Oral

In Vitro Use Guide

Was investigated the effects of NT-702 (PAROGRELIL) on arterioles isolated from rabbit lumbar spinal cords. NT-702 caused a dose-dependent dilation of the isolated spinal arterioles. The disruption of endothelium produced a significant reduction of higher concentrations(10(-7) and 10(-6) M), but not lower concentrations (less than 10(-8) M), of NT-702-induced vasodilation. The NT-702-induced vasodilation of the arterioles with endothelium was not affected by pretreatment with an inhibitor of nitric oxide, cyclooxygenase, or cytochrome P-450 monooxygenase. In contrast, catalase reduced significantly the higher concentrations of NT-702-induced vasodilation only.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:01:11 GMT 2025` Edited by `admin` on `Mon Mar 31 18:01:11 GMT 2025`
Record UNII	65O9DMS368
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PAROGRELIL HYDROCHLORIDE

Common Name

English

NM-702

Preferred Name

English

3(2H)-PYRIDAZINONE, 4-BROMO-6-(3-(4-CHLOROPHENYL)PROPOXY)-5-((3-PYRIDINYLMETHYL)AMINO)-, HYDROCHLORIDE (1:1)

Systematic Name

English

Code System Code Type Description

PUBCHEM

9848253